TG THERAPEUTICS INC.;RHIZEN PHARMACEUTICALS SA;LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
发明人:
申请号：
IL23856415
公开号：
IL238564D0
申请日:
2015.04.30
申请国别(地区):
IL
年份:
2015
代理人:
摘要：
Highly effective combinations of a compound of formula A (a PI3K´ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K´ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
